Connect with us

3 “Strong Buy” Healthcare Stocks That Could Double in the Next Year

3 "Strong Buy” Healthcare Stocks That Could Double in the Next Year



Out on Wall Street, stocks were able to pull out a major win. Despite being a more volatile week of trading, the three major U.S. stock indexes were each able to notch a more than 3% weekly-gain, with the Dow Jones exhibiting its best weekly performance since April 9. The surge came as investors applauded progress related to a COVID-19 vaccine and the reopening of the U.S. economy. 

Against this backdrop, investor focus has locked in on one area of the market in particular: the healthcare sector. Amid the COVID-19 pandemic, the space has held up strong, broadly outperforming the rest of the market. Not to mention return-minded investors tend to flock to these names thanks to the possibility of sky-high rewards.  

What’s the secret to their huge return potential? The nature of the industry itself. Many healthcare companies only rely on a few key indicators such as study results or regulatory approvals to determine if there’s a clear path forward, and thus, a single piece of good news can launch it on an upward trajectory. However, the opposite also holds true, so these tickers are notoriously risky. 

Understanding the volatile nature of the industry, we used TipRanks’ database to pinpoint compelling plays within the healthcare space. The platform helped us track down three that have received overwhelmingly bullish support from analysts, enough to earn a “Strong Buy” consensus rating. The cherry on top? Each could double in the twelve months ahead.  

NuCana PLC (NCNA) 

Using its ProTide technology to turn some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines, NuCana hopes to improve treatment outcomes for cancer patients. With the company gearing up for a jam-packed year of potential catalysts, several members of the Street believe that now is the time to snap up shares. 

At the beginning of May, NCNA announced that it had restarted enrollment for its Phase 3 NuTide:121 trial, which is examining Acelarin and cisplatin in front-line biliary tract cancer (BTC) patients. Weighing in on the good news for H.C. Wainwright is five-star analyst Robert Burns. He reminds clients that the initial data from the Phase 1 ABC-08 front-line locally advanced or metastatic BTC trial, which was presented at ASCO 2019, demonstrated that within the intent-to-treat (ITT) population, the therapy produced a 50% unconfirmed objective response rate (ORR) and 7% complete response (CR) rate.  

“We believe this compares favorably to results that Valle and colleagues presented in their 2010 New England Journal of Medicine paper examining gemcitabine plus cisplatin (n=204) in a front-line BTC Phase 3 trial,” Burns commented. As a result, he thinks data from the trial could fuel significant upside. 

If that wasn’t enough, a few weeks later, NCNA revealed that enrollment for the Phase 1 and Phase 1b trials of its NUC-3373 candidate in metastatic colorectal cancer (mCRC) and in advanced solid tumors, respectively, were resumed. Enrollment for the Phase 1 NuTide:701 trial evaluating NUC-7738 in patients with advanced solid tumors also kicked off again. Early data from these trials is slated for release later this year.  

Burns points out that there are several other key catalysts on the horizon including the readout of data from the Phase 1b ABC-08 trial of Aclearin and cisplatin in first-line BTC, an update regarding the enrollment status for the Phase 3 trial of Acelarin and gemcitabine in first-line BTC as well as the initiation of a Phase 2/3 trial of NUC-3373 in conjunction with other agents in mCRC. 

Based on all of the above, Burns stayed with the bulls. Along with a Buy rating, the $16 price target remains unchanged. Should this target be met, a twelve-month gain of 173% could be in store. (To watch Burns’ track record, click here)     

Do other analysts agree with Burns? As it turns out, they do. With 100% Street support, or 3 Buy ratings to be exact, the message is clear: NCNA is a Strong Buy. At $16, the average price target matches Burns’. (See NuCana stock analysis on TipRanks

Celyad (CYAD) 

Moving right along, we come across Celyad, which is developing innovative CAR-T NK cell-based immunotherapies that could potentially treat cancer. As the second half of 2020 will feature major catalysts, it’s no wonder the analyst community is excited about this name.  

In the near-term, Celyad will present updated data from the Phase I alloSHRINK study of CYAD-101, its therapy designed as a treatment for mCRC, at the virtual ASCO conference on May 29 through 31. Using non-gene editing technology, the therapy has already shown anti-tumor activity in two out of twelve patients with a partial response and five patients with stable disease with a minimum of three months of duration.  

Representing H.C. Wainwright, five-star analyst Edward White is optimistic that the outcome will be favorable. He explained, “To date, CYAD-101 alloSHRINK has not demonstrated clinical evidence of GvHD or dose limiting toxicities.” 

Looking forward, CYAD will read out preliminary data from the Phase 1 THINK trial involving its candidate, CYAD-01, a CAR-T that uses natural killer cell specificity to target T-cells against a broad range of tumors, without preconditioning in patients with r/r AML and MDS, and the DEPLETHINK trial utilizing preconditioning with Cy/Flu. Both of these trials use the OptimAb manufacturing process, but White points out that the company will decide which protocol to proceed with based on the data.  

Some investors expressed concern after COVID-19 forced the company to push back the previously expected timing for the THINK and DEPLETHINK trial readouts, but White was unphased by the delay. “THINK data presented at the American Society of Hematology (ASH) Annual Meeting 2019 showed that 53% (8/15) of evaluable patients demonstrated anti-leukemic activity with bone marrow blasts decrease, including five patients with objective responses and one patient with stable disease (SD) for at least three months,” he stated. The analyst added, “No objective responses had been shown at the time of presentation, but safety data demonstrated that CYAD-01 manufactured with OptimAb was well tolerated following preconditioning chemotherapy.” 

With a decision on which protocol CYAD will pursue expected by year end 2020, the deal is sealed for White. In addition to reiterating his Buy recommendation, he kept the $37 price target as is. This target conveys his confidence in CYAD’s ability to soar 339% in the next year. (To watch White’s track record, click here)     

All in all, other analysts echo White’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $27.33 average price target, the upside potential comes in at 224%. (See Celyad stock analysis on TipRanks)      

IDEAYA Biosciences Inc. (IDYA) 

Last but not least we have IDEAYA, which is developing targeted oncology drugs including the PKC inhibitor, IDE196, for the treatment of metastatic uveal melanoma (MUM) as well as a portfolio of synthetic lethality drug candidates. On the heels of the acceptance of four abstracts for presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will be held on June 22-24, many Wall Street analysts have been impressed.  

Among the bulls is Oppenheimer’s Kevin DeGeeter. He tells investors that he sees two abstracts as being especially promising as both have the potential “to inform clinical studies to start within the next twelve months.” Specifically looking at abstract 1956, “In vitro and in vivo characterization of novel MAT2A allosteric inhibitors”, the five-star analyst believes it is a “placeholder and most likely potential source of upside for IDYA shares.” 

DeGeeter added, “Specifically, we are cautiously optimistic abstract 1956 may more fully describe the cellular anti-proliferation activity and PK profile from a scaffold of IDYA's lead synthetic lethality program, a small molecule allosteric inhibitor of MAT2A... If management opts to disclose cellular anti-proliferation activity or cellular SAM modulation data. In the absence of efficacy data, we would view clean liver tox profile as a material finding.” 

In addition, DeGeeter pointed out, “Our investment thesis for shares of IDYA is based in large measure on the potential of the company’s broad pipeline of synthetic lethality programs.” As a result, he argues that the selection of a development candidate for lead synthetic lethality program, MAT2A, which is slated for Q2 2020, and the IND filing expected in Q4 2020, represent key catalysts. He also thinks AACR is a “logical” timeframe to confirm selection. It should be noted previous studies have demonstrated that MAT2A regulates PMRT5 expression. 

To top it all off, DeGeeter believes abstract 5337 will provide more clarity regarding the magnitude of a potential synergy of IDE196 with a MEK inhibitor. The results could help IDYA select patients for a basket study of IDE196. 

To this end, DeGeeter left an Outperform rating and $17 price target on the stock. Given this target, shares could skyrocket 143% in the next twelve months. (To watch DeGeeter’s track record, click here)  

Turning now to the rest of the Street, other analysts also like what they’re seeing. 3 Buys and no Holds or Sells have been assigned in the last three months, making the consensus rating a Strong Buy. While less aggressive than DeGeeter’s, the $15 average price target still leaves room for 115% upside potential. (See IDEAYA stock analysis on TipRanks)    

The post 3 "Strong Buy” Healthcare Stocks That Could Double in the Next Year appeared first on TipRanks Financial Blog.

Read More

Continue Reading


“Spam Strike” Looms After Hormel Minnesota Workers Reject Contract Offer

"Spam Strike" Looms After Hormel Minnesota Workers Reject Contract Offer

By Nathan Owens of Agricultural Dive


Meatpacking workers…



"Spam Strike" Looms After Hormel Minnesota Workers Reject Contract Offer

By Nathan Owens of Agricultural Dive


  • Meatpacking workers at Hormel Foods’ plant in Austin, Minnesota, voted to reject a “final offer” contract last week in a push for stronger wages, setting the stage for a potential strike at the processor’s largest facility.

  • “It’s simply not good enough,” said the United Food and Commercial Workers Local 663 bargaining committee, which represents close to 95% of workers at Hormel’s hometown plant. “Hormel’s record profits are just wages not shared fairly with the rest of us.”

  • A Hormel spokesperson said that the parties have agreed on a contract extension through Oct. 8 as negotiations continue. The Austin plant is the largest of Hormel’s manufacturing locations, employing 1,800 people and producing more than 1 billion pounds of Spam, pepperoni and other food items each year.

Meatpacking workers “overwhelmingly” voted down Hormel’s contract offer, according to UCFW, with the rejection coming as thousands around the U.S. mobilize to demand big businesses provide better working conditions and distribute record profits.

Detroit auto workers for Ford, GM and Stellantis — known as the Big Three — are on day six of a walk-out strike, pressuring automakers for better benefits and pay as they see record high profits. The Writers Guild of America is expected to resume talks today with major Hollywood studios to improve worker compensation and protections around the use of artificial intelligence, Reuters reported. Nurses, teachers, truck drivers and other essential workers are also in the fight against stagnant wages amid inflation.

“The reality is that we keep Hormel running,” the UFCW Local 633 committee said.

“We demand that Hormel does better and comes to the table for a fair agreement quickly.”

Voting took place Sept. 13 and 14 at the plant and UFCW union hall in Austin. Workers are pushing for higher wages in light of Hormel’s high earnings results, which soared as food companies adjusted their sales prices to compensate for absorbed costs.

Hormel’s gross profits totaled $2.05 billion over the past 12 months, though the company is currently grappling with financial headwinds. The pork processor warned investors of lower than expected earnings this year as it navigated through a period of volatile commodity markets.

“We are disappointed in the vote, especially given the significant contract package offered, however we remain optimistic that we will reach agreement,” the Hormel spokesperson said.

Tyler Durden Sun, 09/24/2023 - 17:20

Read More

Continue Reading


Zelenskyy, Trudeau Honor Actual 3rd Reich Nazi With Standing Ovation

Zelenskyy, Trudeau Honor Actual 3rd Reich Nazi With Standing Ovation

Canadian Prime Minister Justin Trudeau and Ukrainian President Volodomyr…



Zelenskyy, Trudeau Honor Actual 3rd Reich Nazi With Standing Ovation

Canadian Prime Minister Justin Trudeau and Ukrainian President Volodomyr Zelenskyy - who commands a battalion of neo-Nazis - honored an actual WWII Nazi with a standing ovation on Friday.

Yaroslav Hunka, 98, fought in a Third Reich military formation accused of war crimes.

On Friday, he was honored during a session of Canadian parliament in which Zelenskyy addressed the lawmakers to thank them for their support since Russia invaded Ukraine, saying that Canada has always been on "the bright side of history."

Hunka stood for standing ovation and saluted, according to Canadian television.

According to the Associated Press, Hunka "fought with the First Ukrainian Division in World War II before later immigrating to Canada," another name for the 14th Waffen Grenadier Division of the SS, the Nazi party's military wing, also known as the SS Galichina.


Formed in 1943, SS Galichina was comprised of Ukrainians from the Galicia region in the western part of the country. It was armed and trained by Hitler's Nazis and commanded by German officers. The next year, the division received a visit from SS head Heinrich Himmler, who had high praise for the unit's effectiveness at slaughtering Poles.

The SS Galichina subunits were responsible for the Huta Pieniacka massacre, in which they burned 500 to 1,000 Polish villagers alive.

One of several photos on a blog by an SS Galichina veterans’ group that shows Yaroslav Hunka, the Ukrainian immigrant honored by the Canadian Parliament during a visit by Ukrainian President Volodymyr Zelenskyy. Hunka is in the front row, middle.

In fact, during the Nuremberg Trials, the Waffen-SS was declared to be a criminal organization responsible for mass atrocities.

Following the war, thousands of SS Galichina veterans were allowed to leave Germany and resettle in the West - with around 2,000 moving to Canada. By that time, they were known as the First Ukrainian Division.

A blog by an association of its veterans, called “Combatant News” in Ukrainian, includes an autobiographical entry by a Yaroslav Hunka that says he volunteered to join the division in 1943 and several photographs of him during the war. The captions say the pictures show Hunka during SS artillery training in Munich in December 1943 and in Neuhammer (now Świętoszów), Poland, the site of Himmler’s visit. 

In posts to the blog dated 2011 and 2010, Hunka describes 1941 to 1943 as the happiest years of his life and compares the veterans of his unit, who were scattered across the world, to Jews. -Forward

So, the same leftists who called Trump supporters Nazis for years are now honoring an actual Nazi - while Germany has notably locked up several concentration camp guards in their 90s for their involvement in Nazi activities.

University of Ottawa Political Scientist Ivan Katchanovski lays it out...

Meanwhile, here's Ukraine's Azov Battalion of neo-Nazis that everyone with a Ukraine flag in their bio is supporting...

Odd, they don't look like Trump supporters.

Maybe these Nazis can shed some light? Careful, "X" thinks this is sensitive material (that might redpill people?).


Tyler Durden Sun, 09/24/2023 - 14:25

Read More

Continue Reading


Kerry Acknowledges Need For Nuclear Power As Climate Diplomacy Dominates New York City

Kerry Acknowledges Need For Nuclear Power As Climate Diplomacy Dominates New York City

Authored by Nathan Worcester via The Epoch Times,




Kerry Acknowledges Need For Nuclear Power As Climate Diplomacy Dominates New York City

Authored by Nathan Worcester via The Epoch Times,

While addressing an Atlantic Council meeting on nuclear energy, U.S. Climate Envoy John Kerry made it clear he doesn't think wind and solar alone will be sufficient to meet global energy needs while achieving policy plans to rapidly scale back the use of hydrocarbons in the name of addressing climate change risks as outlined by the United Nations.

"You will have to have some component of nuclear—yet to be determined how big or where it'll go. That's going to be a market-based reaction," said Mr. Kerry, who served as a Democratic senator from Massachusetts before serving as Secretary of State under former President Barack Obama.

The 2004 Democratic candidate for president said that "most scientists will tell you" the goal of Net Zero 2050 cannot be achieved "unless we have a pot, a mixture of energy approaches."

"Clearly, we're going to need nuclear to be a part of that," he said on Monday.

Mr. Kerry's pro-nuclear remarks come as climate-related diplomacy and other climate-themed events overtake New York City.

Over the weekend, protesters demonstrated against fossil fuels in the streets of New York City, with Rep. Alexandria Ocasio Cortez (D-N.Y.) among the participants.

Mr. Kerry voiced support for those demonstrators in his speech to the Atlantic Council.

In addition, the U.N. will hold its inaugural Climate Ambition Summit on Sept. 20.

U.N. statement on the event states it "will showcase leaders who are 'first movers and doers' from government, business, finance, local authorities, and civil society who have credible actions, policies and plans to keep the 1.5°C degree goal of the Paris Agreement alive and deliver climate justice to those on the front lines of the climate crisis."

The Climate Ambition Summit comes ahead of the next annual United Nations Climate Change Conference, which will begin in late November. It's taking place in Dubai, United Arab Emirates.

Even as he praised climate protesters, Mr. Kerry noted that a previous generation of environmental activists had fought hard against nuclear power, now seen as a pragmatic solution by many climate hawks.

"In my state of Massachusetts, where there was a huge fight over Seabrook Nuclear Plant in New Hampshire, we now happily get about 20 percent of all our energy from Seabrook, and nobody's complaining—maybe about the prices a little bit, because that's normal in today's world," he said.

A view of the Seabrook Nuclear Power Plant in Seabrook, N.H., on March 21, 2011. (Emmanuel Dunand/AFP via Getty Images)

"The United States is now therefore committed, based on experience and based on reality, to trying to accelerate the deployment of nuclear energy, as part of the Biden program," he added.

The diplomat, who came under fire from Republicans earlier this summer for his unwillingness to share details of his staff at a Congressional hearing, commented positively on Bill Gates' TerraPower, which plans to build the next-generation Natrium nuclear reactor in Wyoming.

He also drew attention to his recent trip to Romania, where he visited a control room simulator for a small modular reactor developed by the American firm NuScale.

Mr. Kerry took issue with the continued construction of unabated coal-fired power plants and with the existence of subsidies for fossil fuels.

An International Monetary Fund (IMF) study identified $1.3 trillion in "explicit" subsidies for fossil fuels in 2022, a stark increase from $500 billion in 2020. Such subsidies are ascribed to fossil fuel prices when they are lower than they would otherwise be if producers fully bore supply costs. The IMF authors attributed a substantial proportion of the increase to "temporary price support measures," in line with surging fossil fuel prices during that period.

Whitehouse Touts ADVANCE Act

Mr. Kerry wasn't the only high-level Democratic politician who addressed the Atlanticist forum on Monday.

In pre-recorded remarks, Sen. Sheldon Whitehouse (D-R.I.) touted the bipartisan, nuclear power-related ADVANCE Act, which passed the Senate as part of the National Defense Authorization Act (NDAA) in July. The bill has not moved ahead in the House.

"Our legislation would strengthen the Nuclear Regulatory Commission's ability to safely and efficiently review the expected influx of applications and prepare them to license HALEU [high-assay low-enriched uranium] fuels," the lawmaker said.

Russia currently dominates the production of HALEU fuels, which are key for most next-generation nuclear reactors. Uncertainty about Russian supplies of HALEU has been a worry for TerraPower and a central motivation for the Nuclear Fuel Security Act, another successful NDAA amendment.

"We spend nearly $1 billion each year on Russian uranium. Russia uses these revenues to fund its invasion of Ukraine," Sen. John Barrasso (R-Wyo.) said in the Senate as the measure was under consideration.

Sen. John Barrasso (R-Wyo.) in Washington on Dec. 1, 2020. (Bill O'Leary-Pool/Getty Images)

'Decarbonize Beyond Electricity'

Other speakers at the event expanded on how nuclear energy could be used to cut carbon emissions.

"We need to decarbonize beyond electricity," said John Wagner, director of the Idaho National Laboratory. He cited industrial heating and hydrogen production as examples of such applications for nuclear energy.

Sama Bilbao y León, director general of the World Nuclear Association, concurred.

"Yes, we need to electrify as much as we can of our economy, but it is not going to be possible to electrify everything," she said.

Ben Pickett of Nucor Corporation, which operates mills that recycle scrap steel using electric arc furnaces, explained that his company's operations require "billions and billions of kilowatt hours per year."

Earlier this year, Nucor signed a memorandum of understanding with NuScale Power. The latter could potentially develop small modular reactors for use in conjunction with Nucor's steel production facilities.

"We've got customers now that are demanding much cleaner steels," Mr. Pickett said.

He conceded that the idea of running steel production on advanced nuclear has met with a "mixed" reaction in his industry.

Tyler Durden Sun, 09/24/2023 - 15:00

Read More

Continue Reading